Literature DB >> 14676463

Validation of a mathematical model predicting the response to growth hormone treatment in prepubertal children with idiopathic growth hormone deficiency.

J Vosahlo1, T Zidek, J Lebl, S Riedl, H Frisch.   

Abstract

OBJECTIVE: To validate a mathematical model developed by Ranke et al. (J Clin Endocrinol Metab 1999;84:1174-7783) to predict the GH response during the first years of GH replacement therapy. PATIENTS AND METHODS: 38 children with idiopathic GH deficiency (GHD) met all inclusion criteria for the prediction model, but the group differed in some characteristics from the cohort from which the model was derived.
RESULTS: Using the model for the 1st year including maximum GH after stimulation and the equation for the 6th year, the predicted value corresponded well with actual height gain. Differences were found when the growth response of the 1st year excluding maximum GH and that of the 2nd-5th year were calculated, resulting in a significant underestimation of actual height gain (-0.63 to -1.07 cm/year).
CONCLUSION: The mathematical prediction model tended to underpredict the growth response to GH treatment in our patients with pronounced GHD. The severity of GHD seems to be an important parameter for the 1st year prediction. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676463     DOI: 10.1159/000075590

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  2 in total

1.  A mathematical model in the analysis of the response to growth hormone treatment in pediatric patients with diagnosis of growth hormone deficiency.

Authors:  G Migliaretti; P Berchialla; A Borraccino; D Gregori; F Cavallo
Journal:  J Endocrinol Invest       Date:  2012-02       Impact factor: 4.256

2.  Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study.

Authors:  M Cappa; L Iughetti; S Loche; M Maghnie; A Vottero
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.